List of Detectnet drug patents

Detectnet is owned by Radiomedix.

Detectnet contains Copper Dotatate Cu-64.

Detectnet has a total of 3 drug patents out of which 0 drug patents have expired.

Detectnet was authorised for market use on 03 September, 2020.

Detectnet is available in solution;intravenous dosage forms.

Detectnet can be used as use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients.

Drug patent challenges can be filed against Detectnet from September, 2024.

The generics of Detectnet are possible to be released after 23 August, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 3, 2025
Orphan Drug Exclusivity (ODE) Sep 3, 2027

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic